Table 4.
Baseline demographical and clinical characteristics of adult patients who received allo-HSCT due to leukemia.
| Variables | Cohort (N = 3,809) | History of depression | p-value | |
|---|---|---|---|---|
| Yes (N = 613) | No (N = 3,196) | |||
| Median age at transplant, year (range) | 47 (18–74) | 49(18–72) | 46(18–74) | < 0.0001 |
| Under 47, no (%) | 1809 (52.2%) | 344 (56.1%) | 1,465 (45.8%) | |
| Over 47, no (%) | 2000 (47.8%) | 269 (43.9%) | 1731 (54.2%) | |
| Gender | ||||
| Male, no (%) | 2055 (54.0%) | 255 (41.6%) | 1,800 (56.3%) | < 0.0001 |
| Anxiety | ||||
| No | 2,909 (76.4%) | 305 (49.8%) | 2,604 (81.5%) | |
| Yes | 900 (23.6%) | 308 (50.2%) | 592 (18.5%) | |
| Stem cell source | 0.114 | |||
| Bone marrow, no (%) | 469 (12.3%) | 62 (10.1%) | 407 (12.7%) | |
| Peripheral blood, no (%) | 3,246 (85.2%) | 534 (87.1%) | 2,712 (84.9%) | |
| Unclassified, no (%) | 94 (2.5%) | 17 (2.8%) | 77 (2.4%) | |
| Previous non-hematologic malignancy | 0.010 | |||
| No, no (%) | 3,422 (89.8%) | 528 (86.1%) | 2,894 (90.6%) | |
| Yes, no (%) | 387 (10.2%) | 85 (13.9%) | 302 (9.4%) | |
| Hypertension | 0.005 | |||
| No, no (%) | 1,224 (32.1%) | 378 (61.7%) | 2,207 (69.1%) | |
| Yes, no (%) | 1,224 (32.1%) | 235 (38.3%) | 989 (30.9%) | |
| Diabetes | 0.002 | |||
| No, no (%) | 2,684 (70.5%) | 400 (65.3%) | 1,446 (45.2%) | |
| Yes, no (%) | 1,125 (29.5%) | 213 (34.7%) | 912 (28.5%) | |
| Dyslipidemia | < 0.0001 | |||
| No, no (%) | 1674 (43.9%) | 228 (37.2%) | 1,446 (45.2%) | |
| Yes, no (%) | 2,135 (56.1%) | 385 (62.8%) | 1,750 (54.8%) | |
| COPD | 0.022 | |||
| No, no (%) | 3,618 (95.0%) | 570 (93.0%) | 3,048 (95.4%) | |
| Yes, no (%) | 191 (5.0%) | 43 (7.0%) | 148 (4.6%) | |
| CVD | 0.079 | |||
| No, no (%) | 3,643 (95.6%) | 579 (94.5%) | 3,064 (95.9%) | |
| Yes, no (%) | 166 (4.4%) | 34 (5.5%) | 132 (4.1%) | |
COPD Chronic obstructive pulmonary disease; CVD Cerebro- or cardiovascular disease; HSCT Hematopoietic stem cell transplantation; MDS Myelodysplastic syndrome; MPN myeloproliferative neoplasm.